Morgan Stanley Boosts Insmed on Strong Brinsupri Outlook
Morgan Stanley upgrades Insmed to Overweight and raises price target to $212.
NOTRELOAD AI
Big Move in Autoimmune Space: Aurinia to Buy Kezar Life Sciences
Aurinia Pharmaceuticals has agreed to acquire Kezar Life Sciences for $6.955 in cash per share plus a Contingent Value Right (CVR).
Anthropic’s New AI Model Could Supercharge CrowdStrike’s Growth
Wolfe Research upgrades CrowdStrike to Outperform and sets a $450 price target.
Game-Changer for IPF: Inhaled Tyvaso Preserves Lung Function in Major TETON-1 Study
The United Therapeutics TETON-1 trial shows that inhaled Tyvaso preserves lung function by 130 mL versus placebo and reduces disease progression. Positive results were seen across all patient groups, with an FDA filing planned for this summer.
Viridian’s Elegrobart Data: Promising Proptosis Win, But Missing the Full Picture for Thyroid Eye Disease
Viridian highlights 54% proptosis response for Elegrobart in TED, but secondary endpoints like inflammation and diplopia showed limited gains.
Alcoa Stock Surges Amid Middle East Supply Concerns
Iran’s weekend attacks on major Persian Gulf aluminum plants triggered sharp price jumps. Supply shortages could push aluminum to record highs, affecting planes, solar panels, and packaging.